3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
12
Urinary Bladder Neoplasms
9
Ureteral Neoplasms
4
Urologic Neoplasms
3
Urethral Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Urothelial Cancer
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Triple Negative Breast Neoplasms
1
Salivary Gland Neoplasms
1
Peripheral Nervous System Diseases
1
Penile Squamous Cell Carcinoma (PSCC)
1
Neoplasms by Site
1
Neoplasms
1
Muscle-invasive Bladder Cancer
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Metastatic Urothelial Cancer
1
Male Urogenital Diseases
1
Head and Neck Neoplasms
1
Female Urogenital Diseases
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Carcinoma, Adenoid Cystic
1
Adenocarcinoma of the Bladder
1
Interventions
pembrolizumab
3
fludarabine
3
aldesleukin
3
Cyclophosphamide
3
cabozantinib
2
Specimen Handling
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
Fecal Microbiota Transplantation
2
CTLA-4 Antigen
2
vedolizumab
1
prednylidene
1
olaparib
1
gallium 68 PSMA-11
1
enfortumab vedotin
1
deltacortene
1
darolutamide
1
Therapeutics
1
Standard of Care
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Prednisone
1
Practice Guidelines as Topic
1
Pluvicto
1
Mitomycin
1
Lutetium-177
1
Lutetium
1
Loperamide
1
LDP-02
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
enfortumab vedotin
×
90 days
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled